Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: pulmatrix.com
HC Wainwright & Co. reiterated coverage of Pulmatrix with a rating of Buy and set a new price target of $5.00 from $10.00 previously
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass., March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced fourth quarter and year-end financi
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. ("Cullgen"), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE™ platform to discover and advance therapeutics for the treatment of cancer and other diseases, today announced that it has begun dosing in human subjects to evaluate its potential first-in-class, oral, pan-TRK protein degrader for the treatment of pain. CG001419 is a highly active small molecule designed to selectively degrade both mutant and wild-type TRK proteins and is being developed to be a new, non-opioid, non-NSAID analgesic therapy as part of a new class of pain signal inhibitors that have the
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of cancer and one for the treatment of acute and chronic pain Combined company expected to have approximately $65 million of cash and cash equivalents at close to provide funding through multiple clinical milestones and expected runway through 2026 As part of merger agreement, Pulmatrix intends to divest its assets including its acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology Cullgen and Pulmatrix will host an informational webcast about the propose
Closed transactions with MannKind Corporation validating the potential value of iSPERSE™ technology Pursuing strategic alternatives to further leverage iSPERSE™ and optimize the potential of PUR3100 Completed PUR1900 wind down activities Cash runway projected into Q4 2026 FRAMINGHAM, Mass., Nov. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced third quarter financial results for 2024 and provided a corporate update on its clinical ass
Completed series of transactions with MannKind Corporation validating iSPERSE™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE™ and optimize the potential of PUR3100 FRAMINGHAM, Mass., Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease. Master service agreement in place for MannKind to provide future iSPERSE™ dry powder drug formulation development services to Pulmatrix. BEDFORD, Mass., May 29, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE. Pulmatrix previously received FDA's acceptance of an IND application and a "study may proceed" letter for a Phase 2 study, positioning PUR3100 as Phase 2-ready. BEDFORD, Mass., May 15, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalati
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval outside the United States BEDFORD, Mass., May 10, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary dise
2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix BEDFORD, Mass., March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary di
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix Pulmatrix to significantly reduce cash burn and focus on strategic alternatives that leverage the company's promising pipeline, iSPERSE™ technology and approximately $19 million cash on hand as of 12/31/23 BEDFORD, Mass., Jan. 8, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system diseases, today announced that it has entered int
424B3 - Pulmatrix, Inc. (0001574235) (Filer)
S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
8-K - Pulmatrix, Inc. (0001574235) (Filer)
8-K - Pulmatrix, Inc. (0001574235) (Filer)
10-K - Pulmatrix, Inc. (0001574235) (Filer)
8-K - Pulmatrix, Inc. (0001574235) (Filer)
S-4 - Pulmatrix, Inc. (0001574235) (Filer)
8-K - Pulmatrix, Inc. (0001574235) (Filer)
425 - Pulmatrix, Inc. (0001574235) (Subject)
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to
PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass., March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2022 and provided a corporate update on its development programs.
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
3 - Pulmatrix, Inc. (0001574235) (Issuer)
4 - Pulmatrix, Inc. (0001574235) (Issuer)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)
SC 13D - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G - Pulmatrix, Inc. (0001574235) (Subject)
SC 13G/A - Pulmatrix, Inc. (0001574235) (Subject)